publication date: Jun. 30, 2017

Drugs and Targets FDA approves Vectibix for use in wild-type ras metastatic colorectal cancer

FDA approved the supplemental Biologics License Application for Vectibix (panitumumab) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.

Vectibix is the first-and-only fully human monoclonal anti-epidermal growth factor receptor antibody approved by the FDA for this patient population.

As part of this indication, FDA approved the first multigene, next-generation sequencing-based test to identify the RAS mutation status of a patient’s tumor.

Next-generation sequencing is a novel diagnostics test technique that makes a more personalized medicine approach possible. This companion diagnostic helps physicians identify patients that are more likely to benefit from treatment with Vectibix.

“Of the few biomarkers in colorectal cancer, RAS mutation status provides actionable information when deciding on a first-line treatment option in mCRC patients,” said Marwan Fakih, co-director of the Gastrointestinal Cancer Program at City of Hope, Duarte, Calif.

“Panitumumab has demonstrated a significant overall survival benefit to patients whose mCRC does not have mutations in RAS,” Fakih added, “providing physicians with a novel targeted treatment option and allowing … Continue reading FDA approves Vectibix for use in wild-type ras metastatic colorectal cancer

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.